新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2023-073 新里程健康科技集团股份有限公司 关于 2022 年限制性股票激励计划预留授予登记完成的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 重要内容提示： 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于 2023 年 9 月 18 日召开第六届董事会第十四次会议和第六届监事会第十一次会议 审议通过了《关于向 2022 年限制性股票激励计划激励对象授予预留限制性股票 的议案》。根据《上市公司股权激励管理办法》、深圳证券交易所、中国证券登 记结算有限责任公司深圳分公司有关规定，公司已完成 2022 年限制性股票激励 计划（以下简称"本次激励计划"）预留授予登记工作，现将相关事项公告如下： 一、2022 年限制性股票激励计划已履行的决策程序 1、2022 年 12 月 7 日，公司召开第六届董事会第四次会议，会议审议通过 了《关于公司<2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2022 年限制性股票激励计划实施考核管理办法> ...

证券代码：002219 证券简称：新里程 公告编号：2023-072 2023 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 3.第三季度报告是否经过审计 1 同一控制下企业合并 （一） 主要会计数据和财务指标 新里程健康科技集团股份有限公司 2023 年第三季度报告 新里程健康科技集团股份有限公司 重要内容提示： 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 □是 否 新里程健康科技集团股份有限公司 2023 年第三季度报告 注：报告期内利润包含股权激励费用摊销影响。 一、主要财务数据 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------------------------ ...

资产负债表日，对于当期和以前期间形成的当期所得税负债（或资产），以按照税法规定计算的预期应交纳（或返还） 的所得税金额计量。计算当期所得税费用所依据的应纳税所得额系根据有关税法规定对本报告期税前会计利润作相应调 整后计算得出。 （2）递延所得税资产及递延所得税负债 某些资产、负债项目的账面价值与其计税基础之间的差额，以及未作为资产和负债确认但按照税法规定可以确定其计税 基础的项目的账面价值与计税基础之间的差额产生的暂时性差异，采用资产负债表债务法确认递延所得税资产及递延所 得税负债。 与商誉的初始确认有关，以及与既不是企业合并、发生时也不影响会计利润和应纳税所得额（或可抵扣亏损）的交易中 产生的资产或负债的初始确认有关的应纳税暂时性差异，不予确认有关的递延所得税负债（初始确认的资产和负债导致 产生等额应纳税暂时性差异和可抵扣暂时性差异的单项交易除外）。 此外，对与子公司、联营企业及合营企业投资相关的应纳税暂时性差异，如果本公司能够控制暂时性差异转回的时间， 而且该暂时性差异在可预见的未来很可能不会转回，也不予确认有关的递延所得税负债。 除上述例外情况，本公司确认其他所有应纳税暂时性差异产生的递延所得税负债。 ...

证券代码：002219 证券简称：新里程 新里程健康科技集团股份有限公司 投资者关系活动记录表 编号：2023-03 特定对象调研 □分析师会议 投资者关系活动 □媒体采访 业绩说明会 类别 □新闻发布会 □路演活动 现场参观 □其他 中信建投、中金公司、海通证券、国盛证券、泰康资产、浦银安盛、 参与单位名称（排 慎知资产、银华基金、长信基金、博裕资本、中加基金、华创证券、 名不分先后） 华鑫证券 时间 2023 年 6 月 6 日 9:00-12:00、2023 年 6 月 7 日 9:00-12:00 地点 兰考第一医院（河南兰考）、兖矿新里程总医院（山东邹城） 上市公司接待人员 姓名 董事会秘书、财务总监刘军 兰考第一医院（集团）： 1. 基本情况介绍： 兰考县是河南省直管县，县域面积 1116 平方公里，下辖 3 个街道办事处， 13 个乡镇，人口 87 万； 投资者关系活动主 兰考第一医院（集团）占地面积 140 余亩，建筑面积 12 万平方米，总资 要内容介绍 产 5.2 亿元，实际开放床位 1560 张，年门急诊量 120 万人次，年出院人次 7.5 万，年手术量 2.4 万台，下设机构有兰考第 ...

新里程健康科技集团股份有限公 2023 年第一季度报告 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 1 证券代码：002219 证券简称：新里程 公告编号：2023-044 新里程健康科技集团股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 新里程健康科技集团股份有限公 2023 年第一季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 778,180,614.02 | 761,048,026.55 | 2.25% | | 归属于上 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a year-over-year growth of 15%[4]. - The total revenue for 2022 was ¥3,152,734,880.63, representing a 4.53% increase from ¥3,016,070,733.20 in 2021[141]. - The net profit attributable to shareholders for 2022 was ¥155,621,958.97, a significant recovery from a loss of ¥371,431,516.93 in 2021, marking a 141.90% increase[141]. - The net cash flow from operating activities for 2022 was ¥91,209,535.37, compared to a loss of ¥415,431,630.35 in 2021, indicating a 121.96% improvement[141]. - Basic earnings per share for 2022 were ¥0.0477, a turnaround from a loss of ¥0.1991 in 2021, reflecting a 123.96% increase[141]. - The weighted average return on equity for 2022 was 9.52%, a significant recovery from -381.53% in 2021[141]. - The company reported a non-operating income of 64,412,423.60 yuan in 2022, compared to 44,000,113.42 yuan in 2021, indicating a significant increase[161]. - The company received government subsidies amounting to 17,827,702.87 yuan in 2022, up from 16,865,398.63 yuan in 2021, reflecting continued support for its operations[161]. - The company recorded a gain from debt restructuring of 47,318,475.58 yuan in 2022, compared to 24,336,243.21 yuan in 2021, highlighting improved financial management[161]. User Growth and Market Expansion - User data showed a growth in active users, reaching 5 million by the end of 2022, which is a 20% increase compared to the previous year[4]. - The company provided a positive outlook for 2023, projecting a revenue growth of 10% to 1.32 billion RMB, driven by new product launches and market expansion strategies[4]. - The company plans to expand its market presence by entering three new provinces in 2023, aiming to increase its customer base by 30%[4]. - A strategic acquisition was completed in Q3 2022, enhancing the company's service capabilities and expected to contribute an additional 200 million RMB in revenue annually[4]. Operational Efficiency and Cost Management - The company has committed to reducing operational costs by 15% over the next two years through efficiency improvements and technology integration[4]. - The gross profit margin improved to 40% in 2022, up from 35% in 2021, reflecting better cost management and pricing strategies[4]. - The company is exploring partnerships with local healthcare providers to enhance service delivery and customer engagement, targeting a 25% increase in service utilization[4]. - A new technology platform was launched in late 2022, aimed at improving user experience and expected to drive a 15% increase in user retention rates[4]. Legal and Financial Transactions - The company is involved in a lawsuit regarding a loan contract dispute, with the amount in question being 60 million yuan[19]. - The court has upheld the original ruling, rejecting the company's appeal[20]. - The company has not engaged in any related party transactions involving asset or equity acquisitions or sales during the reporting period[21]. - There are no deposit, loan, credit, or other financial transactions between the company's financial subsidiary and related parties[23]. - The company has provided guarantees totaling 30 million yuan for Wafangdian Third Hospital, which is not yet fulfilled[42]. - The company has also provided guarantees of 4.8 million yuan for Dalian Liaoyu Hospital, which has been fulfilled[42]. - A guarantee of 10 million yuan was provided for Kangxian Duyimai Biological Pharmaceutical Co., which has been fulfilled[42]. - The company has a guarantee of 1.6 million yuan for Pingxiang Ganzi Hospital, which is not yet fulfilled[42]. - The company has not disclosed any entrusted loans during the reporting period[29]. - The company has not made any significant changes to its share capital or shareholder structure during the reporting period[35]. - The company approved a total guarantee amount of 97,600,000 for subsidiaries during the reporting period, with an actual guarantee amount of 59,905,000[43]. - As of the end of the reporting period, the approved guarantee amount for subsidiaries was 127,600,000, with an actual guarantee balance of 51,721,260[43]. - The total actual guarantee amount accounted for 30.02% of the company's net assets[43]. - The company has entrusted 10,100,000 in bank financial products, with no overdue amounts or impairment provisions[44]. - The company has not provided guarantees for shareholders or related parties[43]. - The company has not reported any overdue amounts in its entrusted loans[45]. Shareholder and Capital Structure - The company changed its name from "Hengkang Medical Group Co., Ltd." to "New Journey Health Technology Group Co., Ltd." effective September 26, 2022[45]. - The total share capital increased from 1,865,236,430 shares to 3,264,163,753 shares following a capital reserve conversion plan, with a ratio of 10 shares to 7.5 shares[49]. - The company completed the capital reserve conversion registration on June 22, 2022[49]. - New Mile Health acquired 825,927,323 shares of Hengkang Medical, representing 25.30% of the total share capital after the capital increase[54]. - The total share capital of Hengkang Medical increased from approximately 1,865,236,430 shares to about 3,264,163,753 shares following a capital reserve conversion[53]. - The restructuring plan for Hengkang Medical was approved by the court on April 22, 2022[54]. - New Mile Health is now the controlling shareholder of Hengkang Medical, which has transitioned to a state without a practical controller[54]. - The number of ordinary shareholders increased from 34,517 to 39,935 during the reporting period[55]. - New Mile Health committed to not transferring its shares for 36 months post-acquisition to ensure stable development of Hengkang Medical[63]. - The company reported a significant increase in shareholding concentration with the top shareholder holding over 25%[55]. Goodwill and Impairment - As of December 31, 2022, the goodwill balance of the company was CNY 1,754.51 million, with an impairment provision of CNY 870.41 million, resulting in a net book value of CNY 884.10 million[94]. - The company conducts annual impairment tests on goodwill, which are based on the recoverable amount of asset groups that include goodwill, determined by the higher of the present value of expected future cash flows and the fair value of assets less disposal costs[94]. - The company reported that the key assumptions used in the impairment testing of goodwill are subject to inherent uncertainty and may be influenced by management bias[94]. - The company’s management evaluates the expected credit loss for accounts receivable based on the credit risk characteristics of each receivable[95]. - The total accounts receivable and other receivables amounted to CNY 1,988.91 million, with a bad debt provision of CNY 1,095.97 million, leading to a net value of CNY 892.94 million[95]. - The company reported that the net profit before and after deducting non-recurring gains and losses for the last three accounting years was negative, indicating ongoing uncertainty regarding its ability to continue as a going concern[141]. Strategic Initiatives and Healthcare Focus - The company has shifted its core business model from a single pharmaceutical manufacturing focus to a "big health" industry driven by both medical services and pharmaceutical manufacturing[106]. - The company has implemented a "1+N" development model in the medical sector, which includes a general hospital and multiple specialized hospitals[106]. - The company operates under a "1+N" model, focusing on major diseases related to aging, such as tumors and cardiovascular diseases, to enhance competitiveness and influence in the region[194]. - The company is actively expanding its hospital network, with new tumor hospital licenses approved for Wafangdian Third Hospital and Xuyi Traditional Chinese Medicine Hospital, and ongoing construction of a tumor center at Lankao First Hospital[194]. - The pharmaceutical manufacturing segment aims to create a competitive product matrix and influential consumer industry layout, leveraging the unique properties of its products to enter the fast-moving consumer goods market[197]. - The company emphasizes a "large specialty, strong comprehensive" approach, enhancing hospital rankings and clinical specialty levels, with several departments recognized as key specialties at the municipal and provincial levels[198]. - The company has been recognized for its excellence, with Wafangdian Hospital and Xuyi Traditional Chinese Medicine Hospital listed among the top hospitals in their respective categories[198]. - The ongoing healthcare reforms and increasing demand for quality medical services present significant growth opportunities for the company in the healthcare sector[197]. - The company aims to enhance regional medical center construction to address the imbalance in healthcare resources, particularly in the context of an aging population[168]. - The company emphasizes the importance of balancing economic and social benefits in its development strategy, particularly in the healthcare sector[168]. - The company has committed to promoting the integration of medical and elderly care services, aligning with national strategies to address population aging[167]. Market Trends and Demographics - The aging population in China is projected to reach 414 million by 2035, driving continuous growth in medical service demand[183]. - The total number of medical institutions in China reached 1,030,935 by the end of 2021, with hospitals increasing by 1,176, indicating a growing healthcare infrastructure[166]. - The total number of medical consultations in national healthcare institutions reached 8.47 billion, an increase of 730 million consultations (9.4% growth) compared to the previous year[193]. - The number of inpatient visits in national healthcare institutions was 24.726 million, an increase of 1.713 million visits (7.4% growth) year-on-year, with a resident annual hospitalization rate of 17.5%[193].

证券代码：002219 证券简称：恒康医疗 编号： | --- | --- | --- | |----------------------|------------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动类 | □ | 特定对象调研 □分析师会议 | | 别 | □ | 媒体采访 □业绩说明会 | | | □ | 新闻发布会 □路演活动 | | | √ 现场参观 | | | | □其他 | | | 参与单位名称及人 | 信达澳银基金 张培培 杜蜀鹏 | | | 员姓名 | 方正证券 刘亚明 兰兰 | | | 时间 | 2015 年 3 月 11 | 日 15:00—16 ： 00 | | 地点 | 四川成都锦江工业开发区金石路 | 456 号公司会议室 | | 上市公司接待人员 | 董事会秘书 薛迪桦 | | | 姓名 | | | | 投 资 者 关 系 活 动 | | 问：公司的发展战略是否以医疗服务为主？ | | （电话会议）主要 | | 答：公司 ...

证券代码：002219 证券简称：恒康医疗 恒康医疗集团股份有限公司 投资者关系活动记录表 编号：2015-03 | --- | --- | --- | |----------------------|---------------------------|--------------------------------------------------------------| | | | | | 投资者关系活动类 | □ | 特定对象调研 □分析师会议 | | 别 | √媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □现场参观 | | | | □ 其他 | | | 参与单位名称及人 | | 经济观察报 温淑萍，第一财经 黄思瑜，国际金融报 宋璇，中国经 | | 员姓名 | 营报 张荣旺、张亮， | 21 世纪经济报道 饶守春，经济参考报 吴颖君 | | 时间 | 2015 年 9 月 13 | 日、 14 日 | | 地点 | 大连瓦房店第三医院 | | | 上市公司接待人员 | 董事会秘书 金振声 | | | 姓名 | 瓦房店第三医院院长 宋丽华 | | | 投 ...